JP2014509515A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014509515A5 JP2014509515A5 JP2013558214A JP2013558214A JP2014509515A5 JP 2014509515 A5 JP2014509515 A5 JP 2014509515A5 JP 2013558214 A JP2013558214 A JP 2013558214A JP 2013558214 A JP2013558214 A JP 2013558214A JP 2014509515 A5 JP2014509515 A5 JP 2014509515A5
- Authority
- JP
- Japan
- Prior art keywords
- biomarker
- expression level
- subject
- breast cancer
- eribulin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000090 biomarker Substances 0.000 claims 45
- 206010006187 Breast cancer Diseases 0.000 claims 28
- 208000026310 Breast neoplasm Diseases 0.000 claims 28
- 238000000034 method Methods 0.000 claims 21
- UFNVPOGXISZXJD-JBQZKEIOSA-N eribulin Chemical compound C([C@H]1CC[C@@H]2O[C@@H]3[C@H]4O[C@@H]5C[C@](O[C@H]4[C@H]2O1)(O[C@@H]53)CC[C@@H]1O[C@H](C(C1)=C)CC1)C(=O)C[C@@H]2[C@@H](OC)[C@@H](C[C@H](O)CN)O[C@H]2C[C@@H]2C(=C)[C@H](C)C[C@H]1O2 UFNVPOGXISZXJD-JBQZKEIOSA-N 0.000 claims 20
- 229960003649 eribulin Drugs 0.000 claims 18
- 150000003839 salts Chemical class 0.000 claims 18
- 239000000523 sample Substances 0.000 claims 13
- 210000001519 tissue Anatomy 0.000 claims 9
- 102000015694 estrogen receptors Human genes 0.000 claims 8
- 108010038795 estrogen receptors Proteins 0.000 claims 8
- 102000003998 progesterone receptors Human genes 0.000 claims 8
- 108090000468 progesterone receptors Proteins 0.000 claims 8
- 206010028980 Neoplasm Diseases 0.000 claims 7
- 239000000427 antigen Substances 0.000 claims 5
- 102000036639 antigens Human genes 0.000 claims 5
- 108091007433 antigens Proteins 0.000 claims 5
- 210000000481 breast Anatomy 0.000 claims 5
- 239000003153 chemical reaction reagent Substances 0.000 claims 5
- 239000012634 fragment Substances 0.000 claims 5
- 238000003018 immunoassay Methods 0.000 claims 5
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims 4
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims 4
- 238000004458 analytical method Methods 0.000 claims 3
- 238000001574 biopsy Methods 0.000 claims 3
- 210000001124 body fluid Anatomy 0.000 claims 3
- 102000004169 proteins and genes Human genes 0.000 claims 3
- 108090000623 proteins and genes Proteins 0.000 claims 3
- 230000035945 sensitivity Effects 0.000 claims 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims 2
- 108020004414 DNA Proteins 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 238000006243 chemical reaction Methods 0.000 claims 2
- 238000011984 electrochemiluminescence immunoassay Methods 0.000 claims 2
- 229960000439 eribulin mesylate Drugs 0.000 claims 2
- 238000003752 polymerase chain reaction Methods 0.000 claims 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 1
- 238000012286 ELISA Assay Methods 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 238000000636 Northern blotting Methods 0.000 claims 1
- 238000012341 Quantitative reverse-transcriptase PCR Methods 0.000 claims 1
- 230000003321 amplification Effects 0.000 claims 1
- 238000003556 assay Methods 0.000 claims 1
- 239000012472 biological sample Substances 0.000 claims 1
- 229960002685 biotin Drugs 0.000 claims 1
- 235000020958 biotin Nutrition 0.000 claims 1
- 239000011616 biotin Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 239000010839 body fluid Substances 0.000 claims 1
- 239000002299 complementary DNA Substances 0.000 claims 1
- 210000002808 connective tissue Anatomy 0.000 claims 1
- 239000013068 control sample Substances 0.000 claims 1
- 238000001514 detection method Methods 0.000 claims 1
- 238000000502 dialysis Methods 0.000 claims 1
- 238000002875 fluorescence polarization Methods 0.000 claims 1
- 230000000951 immunodiffusion Effects 0.000 claims 1
- 238000010166 immunofluorescence Methods 0.000 claims 1
- 238000001114 immunoprecipitation Methods 0.000 claims 1
- 210000002751 lymph Anatomy 0.000 claims 1
- 238000005259 measurement Methods 0.000 claims 1
- 108020004999 messenger RNA Proteins 0.000 claims 1
- 108091070501 miRNA Proteins 0.000 claims 1
- 239000002679 microRNA Substances 0.000 claims 1
- 230000035772 mutation Effects 0.000 claims 1
- 210000000019 nipple aspirate fluid Anatomy 0.000 claims 1
- 238000003199 nucleic acid amplification method Methods 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
- 210000002381 plasma Anatomy 0.000 claims 1
- 238000011002 quantification Methods 0.000 claims 1
- 230000002285 radioactive effect Effects 0.000 claims 1
- 238000003127 radioimmunoassay Methods 0.000 claims 1
- 238000012340 reverse transcriptase PCR Methods 0.000 claims 1
- 210000003296 saliva Anatomy 0.000 claims 1
- 230000028327 secretion Effects 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
- 210000004881 tumor cell Anatomy 0.000 claims 1
- 210000002700 urine Anatomy 0.000 claims 1
- 238000001262 western blot Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161454426P | 2011-03-18 | 2011-03-18 | |
| US61/454,426 | 2011-03-18 | ||
| PCT/US2012/029479 WO2012129100A1 (en) | 2011-03-18 | 2012-03-16 | Methods and compositions for predicting response to eribulin |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017046070A Division JP6612280B2 (ja) | 2011-03-18 | 2017-03-10 | エリブリンに対する応答を予測するための方法及び組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2014509515A JP2014509515A (ja) | 2014-04-21 |
| JP2014509515A5 true JP2014509515A5 (enExample) | 2015-04-23 |
Family
ID=45879070
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013558214A Pending JP2014509515A (ja) | 2011-03-18 | 2012-03-16 | エリブリンに対する応答を予測するための方法及び組成物 |
| JP2017046070A Expired - Fee Related JP6612280B2 (ja) | 2011-03-18 | 2017-03-10 | エリブリンに対する応答を予測するための方法及び組成物 |
| JP2019069638A Pending JP2019150027A (ja) | 2011-03-18 | 2019-04-01 | エリブリンに対する応答を予測するための方法及び組成物 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017046070A Expired - Fee Related JP6612280B2 (ja) | 2011-03-18 | 2017-03-10 | エリブリンに対する応答を予測するための方法及び組成物 |
| JP2019069638A Pending JP2019150027A (ja) | 2011-03-18 | 2019-04-01 | エリブリンに対する応答を予測するための方法及び組成物 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US9637795B2 (enExample) |
| EP (1) | EP2686441B1 (enExample) |
| JP (3) | JP2014509515A (enExample) |
| CN (1) | CN103562406B (enExample) |
| CA (1) | CA2828959A1 (enExample) |
| ES (1) | ES2731653T3 (enExample) |
| SG (2) | SG193489A1 (enExample) |
| WO (1) | WO2012129100A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20120058178A1 (en) | 2009-03-30 | 2012-03-08 | Eisai R&D Management Co., Ltd. | Liposome Composition |
| AU2013353745A1 (en) * | 2012-12-04 | 2015-06-11 | Eisai R&D Management Co., Ltd. | Use of eribulin in the treatment of breast cancer |
| RU2672585C2 (ru) * | 2013-06-26 | 2018-11-16 | Эйсай Ар Энд Ди Менеджмент Ко., Лтд. | Применение эрибулина и ленватиниба в качестве комбинированной терапии для лечения рака |
| US20170100367A1 (en) * | 2014-05-28 | 2017-04-13 | Eisai R&D Management Co., Ltd. | Use of eribulin in the treatment of cancer |
| EP3148336B1 (en) * | 2014-05-28 | 2019-10-02 | Eisai R&D Management Co., Ltd. | Eribulin and poly (adp ribose) polymerase (parp) inhibitors as combination therapy for the treatment of cancer |
| RU2737216C2 (ru) | 2015-03-04 | 2020-11-26 | Мерк Шарп Энд Дохме Корп. | Комбинация антагониста pd-1 и эрибулина для лечения рака |
| WO2016178374A1 (ja) * | 2015-05-01 | 2016-11-10 | 国立研究開発法人科学技術振興機構 | 腫瘍細胞の悪性化抑制剤及び抗腫瘍剤 |
| CN114191563A (zh) | 2016-03-02 | 2022-03-18 | 卫材研究发展管理有限公司 | 基于艾日布林的抗体-药物偶联物和使用方法 |
| US12029724B2 (en) | 2016-04-28 | 2024-07-09 | Eisai R&D Management Co., Ltd. | Method for inhibiting tumor growth |
| US11419856B2 (en) | 2017-11-20 | 2022-08-23 | Basilea Pharmaceutica International AG | Pharmaceutical combinations for use in the treatment of neoplastic diseases |
| WO2020179712A1 (en) * | 2019-03-01 | 2020-09-10 | Eisai R&D Management Co., Ltd. | Methods for predicting tumor response to eribulin |
| US12036204B2 (en) | 2019-07-26 | 2024-07-16 | Eisai R&D Management Co., Ltd. | Pharmaceutical composition for treating tumor |
| US11083705B2 (en) | 2019-07-26 | 2021-08-10 | Eisai R&D Management Co., Ltd. | Pharmaceutical composition for treating tumor |
| CN113174427B (zh) * | 2021-04-29 | 2023-02-28 | 遵义医科大学 | 基于DNA分子检测ERGIC3 mRNA的方法 |
| CN113512733B (zh) * | 2021-05-13 | 2022-07-26 | 浙江工业大学 | 一种电化学nhk反应合成艾日布林中间体的方法 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US5075216A (en) | 1988-09-23 | 1991-12-24 | Cetus Corporation | Methods for dna sequencing with thermus aquaticus dna polymerase |
| US6040138A (en) | 1995-09-15 | 2000-03-21 | Affymetrix, Inc. | Expression monitoring by hybridization to high density oligonucleotide arrays |
| US5143854A (en) | 1989-06-07 | 1992-09-01 | Affymax Technologies N.V. | Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof |
| US5744101A (en) | 1989-06-07 | 1998-04-28 | Affymax Technologies N.V. | Photolabile nucleoside protecting groups |
| US5800992A (en) | 1989-06-07 | 1998-09-01 | Fodor; Stephen P.A. | Method of detecting nucleic acids |
| DE69233087T2 (de) | 1991-11-22 | 2003-12-24 | Affymetrix, Inc. (N.D.Ges.D.Staates Delaware) | Verfahren zur Herstellung von Polymerarrays |
| EP1262564A3 (en) | 1993-01-07 | 2004-03-31 | Sequenom, Inc. | Dna sequencing by mass spectrometry |
| US5556752A (en) | 1994-10-24 | 1996-09-17 | Affymetrix, Inc. | Surface-bound, unimolecular, double-stranded DNA |
| US5545531A (en) | 1995-06-07 | 1996-08-13 | Affymax Technologies N.V. | Methods for making a device for concurrently processing multiple biological chip assays |
| US5854033A (en) | 1995-11-21 | 1998-12-29 | Yale University | Rolling circle replication reporter systems |
| EP0880598A4 (en) | 1996-01-23 | 2005-02-23 | Affymetrix Inc | RAPID EVALUATION OF NUCLEIC ACID ABUNDANCE DIFFERENCE, WITH A HIGH-DENSITY OLIGONUCLEOTIDE SYSTEM |
| WO1999023254A1 (en) | 1997-10-31 | 1999-05-14 | Affymetrix, Inc. | Expression profiles in adult and fetal organs |
| US6020135A (en) | 1998-03-27 | 2000-02-01 | Affymetrix, Inc. | P53-regulated genes |
| CN1216051C (zh) | 1998-06-17 | 2005-08-24 | 卫材株式会社 | 大环类似物及其使用和制备的方法 |
| US8097648B2 (en) | 1998-06-17 | 2012-01-17 | Eisai R&D Management Co., Ltd. | Methods and compositions for use in treating cancer |
| US6653341B1 (en) | 1998-06-17 | 2003-11-25 | Eisai Co., Ltd. | Methods and compositions for use in treating cancer |
| WO2005032347A2 (en) * | 2003-10-01 | 2005-04-14 | The Ohio State University Research Foundation | Determining the chemosensitivity of cells to cytotoxic agents |
| EP1831697A4 (en) * | 2004-12-09 | 2011-01-26 | Eisai R&D Man Co Ltd | SCREENING OF TUBULIN ISOTYPE IN CANCER THERAPY USING ANALOGUES OF HALICHONDRIN B |
| US20110217297A1 (en) * | 2010-03-03 | 2011-09-08 | Koo Foundation Sun Yat-Sen Cancer Center | Methods for classifying and treating breast cancers |
-
2012
- 2012-03-16 CA CA2828959A patent/CA2828959A1/en not_active Abandoned
- 2012-03-16 CN CN201280013701.8A patent/CN103562406B/zh not_active Expired - Fee Related
- 2012-03-16 WO PCT/US2012/029479 patent/WO2012129100A1/en not_active Ceased
- 2012-03-16 US US14/001,737 patent/US9637795B2/en not_active Expired - Fee Related
- 2012-03-16 EP EP12710643.3A patent/EP2686441B1/en active Active
- 2012-03-16 ES ES12710643T patent/ES2731653T3/es active Active
- 2012-03-16 SG SG2013069646A patent/SG193489A1/en unknown
- 2012-03-16 JP JP2013558214A patent/JP2014509515A/ja active Pending
- 2012-03-16 SG SG10201602147YA patent/SG10201602147YA/en unknown
-
2017
- 2017-03-10 JP JP2017046070A patent/JP6612280B2/ja not_active Expired - Fee Related
-
2019
- 2019-04-01 JP JP2019069638A patent/JP2019150027A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014509515A5 (enExample) | ||
| JP2019150027A5 (enExample) | ||
| JP6138154B2 (ja) | 乳癌の予測および診断のためのバイオマーカー | |
| JP2015517801A5 (enExample) | ||
| US10408839B2 (en) | Biomarker panel for diagnosing cancer | |
| JP6192123B2 (ja) | 乳癌の予測および診断のためのバイオマーカー | |
| JP6401702B2 (ja) | 炎症性肝疾患の診断のための方法および組成物 | |
| JP2012517241A5 (enExample) | ||
| JP6749337B2 (ja) | 前立腺抗原標準およびその使用 | |
| JP2012506253A (ja) | 大腸癌関連マーカーを用いた大腸癌の診断キット、及びそれを用いた大腸癌の診断方法 | |
| NO20083820L (no) | Deteksjon av kreft ved forhoyede nivaer av BCL-2 | |
| JP2013500001A5 (enExample) | ||
| JP2012507030A5 (enExample) | ||
| Wu et al. | Development of a highly sensitive glycan microarray for quantifying AFP-L3 for early prediction of hepatitis B virus–related hepatocellular carcinoma | |
| JP2021060418A (ja) | 肝細胞癌および膵臓がんを診断するためのラミニン２の使用 | |
| WO2017039359A1 (ko) | 트립토파닐 티알엔에이 합성효소를 이용한 감염 질환 또는 감염 합병증의 진단용 조성물과 진단 마커 검출 방법 | |
| JP6192122B2 (ja) | 結腸直腸癌診断および予測のためのバイオマーカー | |
| JP2016519767A5 (enExample) | ||
| CN107255711A (zh) | 骨桥蛋白用于制备或筛选慢加急性肝衰竭诊断试剂的用途 | |
| TWI598444B (zh) | 用以評估乳癌罹患風險之方法及基因標記 | |
| WO2020179712A1 (en) | Methods for predicting tumor response to eribulin | |
| KR20130040294A (ko) | 소세포폐암 진단용 조성물 및 소세포폐암 진단키트 | |
| US20230133776A1 (en) | Methods for diagnosing cancer | |
| CN113969312A (zh) | 用于预测溃疡性结肠炎患者对戈利木单抗药物敏感性的标志物 | |
| JP2017529074A (ja) | 治療剤に対する抵抗性の診断に使用するためのＥＲＣＣ１アイソフォーム３のｍＲＮＡおよび／またはタンパク質ならびにこのｍＲＮＡおよび／またはタンパク質を使用する治療剤に対する抵抗性を診断するための方法 |